The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InReflecting resilience within the life sciences sector, Thermo Fisher stock rose 5.14% on May 28 after Q1 results exceeded analyst expectations. The company raised its full-year adjusted EPS guidance, even when accounting for the dilutive sale of its microbiology business. Furthermore, the firm strengthened its market position by launching advanced mass spectrometers and strategically expanding into Sweden's life sciences sector according to reports.
This robust performance comes as sector peers show mixed results; for instance, Danaher (DHR) reported a 7% earnings growth in the latest quarter per market data, while Agilent Technologies faces demand headwinds in China. Compared to the previous quarter, Thermo Fisher demonstrated improved operating margins through cost efficiencies, aligning with sector trends noted in Bloomberg reports regarding a recovery in bioresearch spending.
TMO shares closed at elevated levels on May 28, 2026, with traders monitoring whether momentum can hold above technical support levels derived from recent price action. Looking ahead, investors are eyeing the upcoming CB Consumer Confidence data in the US, which previously printed at 93.1, to gauge how broader consumer health might influence the healthcare and diagnostics sector in the coming weeks.